Afya (NASDAQ:AFYA) CEO Sells $292,110.00 in Stock

Afya Limited (NASDAQ:AFYA) CEO Virgilio Deloy Capobian Gibbon sold 19,500 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $14.98, for a total transaction of $292,110.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Virgilio Deloy Capobian Gibbon also recently made the following trade(s):

• On Tuesday, March 31st, Virgilio Deloy Capobian Gibbon sold 2,320 shares of Afya stock. The stock was sold at an average price of $14.92, for a total transaction of $34,614.40.
• On Thursday, March 26th, Virgilio Deloy Capobian Gibbon sold 800 shares of Afya stock. The stock was sold at an average price of $15.21, for a total transaction of $12,168.00.
• On Wednesday, March 25th, Virgilio Deloy Capobian Gibbon sold 3,900 shares of Afya stock. The stock was sold at an average price of $15.18, for a total transaction of $59,202.00.

Afya Stock Performance

Shares of NASDAQ:AFYA opened at $14.96 on Friday. Afya Limited has a 1 year low of $13.00 and a 1 year high of $19.90. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of 10.25, a price-to-earnings-growth ratio of 0.67 and a beta of 0.48. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.20 and a quick ratio of 0.98. The company’s 50 day simple moving average is $14.47 and its 200 day simple moving average is $14.71.

Afya (NASDAQ:AFYA) last released its earnings results on Wednesday, March 11th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.05. The firm had revenue of $147.08 million during the quarter, compared to analysts’ expectations of $174.74 million. Afya had a return on equity of 18.77% and a net margin of 20.31%. As a group, research analysts predict that Afya Limited will post 1.52 EPS for the current fiscal year.

Afya Dividend Announcement

The firm also recently disclosed an annual dividend, which will be paid on Monday, April 6th. Investors of record on Wednesday, March 25th will be given a dividend of $0.656 per share. This represents a dividend yield of 433.0%. The ex-dividend date is Wednesday, March 25th. Afya’s dividend payout ratio is currently 45.21%.

Afya News Roundup

Here are the key news stories impacting Afya this week:

• Positive Sentiment: Management signaled a strong 2025 and said it is making targeted investments for 2026, suggesting revenue/profit momentum and reinvestment that could support longer‑term growth expectations. Afya Limited Signals Strong 2025, Invests for 2026
• Positive Sentiment: Company announced an annual cash dividend of $0.656 per share (record/ex‑date details in filings). At current levels that equates to roughly a ~4.4% yield, which can attract income‑oriented holders and support the share base. AFYA Stock Page (MarketBeat)
• Neutral Sentiment: Wall Street consensus remains a “Hold” with a mixed set of recent analyst notes and trimmed price targets — this limits near‑term upside from analyst revisions. Afya Limited Receives Consensus Rating of “Hold” from Analysts
• Neutral Sentiment: Public health update from DRC reports the end of Mpox alert — likely marginal to Afya’s Brazil‑focused education business but relevant for broader health‑sector sentiment. DRC: Waziri wa afya atangaza kumalizika kwa tahadhari dhidi ya mlipuko wa Mpox
• Negative Sentiment: CEO Virgilio Deloy Capobian Gibbon disclosed multiple share sales (notably a 19,500‑share block and several other disposals in late March/early April). Large insider sales can be interpreted as a negative signal about near‑term insider conviction or as liquidity/tax planning; the market often reacts negatively to material insider disposals. Afya (NASDAQ:AFYA) CEO Virgilio Deloy Capobian Gibbon Sells 2,320 Shares

Hedge Funds Weigh In On Afya

Institutional investors and hedge funds have recently bought and sold shares of the company. Van ECK Associates Corp raised its position in Afya by 15.7% in the third quarter. Van ECK Associates Corp now owns 10,170 shares of the company’s stock valued at $159,000 after purchasing an additional 1,377 shares during the last quarter. Daiwa Securities Group Inc. acquired a new position in shares of Afya in the fourth quarter valued at approximately $43,000. Arrowstreet Capital Limited Partnership increased its stake in shares of Afya by 5.6% in the second quarter. Arrowstreet Capital Limited Partnership now owns 68,169 shares of the company’s stock valued at $1,217,000 after buying an additional 3,626 shares during the period. Dodge & Cox raised its holdings in Afya by 12.8% in the 2nd quarter. Dodge & Cox now owns 35,262 shares of the company’s stock valued at $630,000 after buying an additional 4,000 shares during the last quarter. Finally, Militia Capital Partners LP bought a new position in Afya in the 2nd quarter valued at approximately $71,000. Institutional investors and hedge funds own 88.02% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on AFYA. JPMorgan Chase & Co. reissued a “neutral” rating and set a $22.00 target price (down from $24.50) on shares of Afya in a research note on Wednesday, January 7th. Wall Street Zen upgraded shares of Afya from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 14th. Zacks Research raised shares of Afya from a “strong sell” rating to a “hold” rating in a report on Monday, March 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of Afya in a research report on Wednesday, January 21st. Finally, UBS Group reissued a “neutral” rating and issued a $16.00 price objective (down from $18.00) on shares of Afya in a research note on Friday, January 16th. One investment analyst has rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $17.30.

Afya Company Profile

Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.

At the core of Afya’s offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.